<img src="https://ml.globenewswire.com/Resource/Download/3f4113d3-b651-4c00-bd96-c1ff9384b1de?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Cullinan_Logo_RGB_CLR.png" alt="Cullinan Therapeutics, Inc."/>Company to host a virtual event today at 8:00 a.m. ETCAMBRIDGE, Mass., Sept. 14, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- <a href="https://www.globenewswire.com/Tracker?data=N6kZUeLrXGbVrcXamntS4W_cESdlhiFvPT78zFnjB8iu5D28Q36OzkVOFcJZFs1esncJoTR86VfItcmN7_458IWZYuNwvQ1uMTSHyD_5_VGphC-tKUl9o_lZYdtf5Zlz" rel="nofollow" target="_blank" title="Cullinan Therapeutics, Inc.">Cullinan Therapeutics, Inc.</a> (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors today at 8:00 a.m. ET to discuss the results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy presented in Presidential Symposium 2 at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer (WCLC). Virtual Event Details Cullinan Therapeutics will host a virtual event for analysts and institutional investors today at 8:00 a.m. ET. Participants from Cullinan Therapeutics include Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, MD, MBA, Chief Medical Officer. A live webcast will be available via the events page of Cullinan Therapeutics’ investor relations website at <a href="https://www.globenewswire.com/Tracker?data=uF1UH3vjp2--OOB-Msv9rldjtXm4LNXyMFgi7nr8muX73KpyYDSebwZ_zy5WcgFy0LiDVSW4iBAbb6DF2b51hsGy-NVepys83ZK550VVm0kCN5iSLiY6N2jRo-uIbwxVa7OnDR2QOmeAA48Av4DA4u5VeK5nq2FuH0Qydm8wtV4=" rel="nofollow" target="_blank" title="">https://investors.cullinantherapeutics.com/events</a>. A replay will be archived on the website following the event. About Cullinan Therapeutics <a href="https://www.globenewswire.com/Tracker?data=N6kZUeLrXGbVrcXamntS4W_cESdlhiFvPT78zFnjB8j-N6yITHoLOGrGLNz5q7yrTfN4Jh5e-TZesDdPklITpXq9BwRpmJNTlYNqj4Rr--q0a4E5F65YeTW9hXvQ-nHv" rel="nofollow" target="_blank" title="Cullinan Therapeutics, Inc.">Cullinan Therapeutics, Inc.</a> (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at <a href="https://www.globenewswire.com/Tracker?data=uF1UH3vjp2--OOB-Msv9rlp5IaQZK123aW70EDaF7GQCEr8sjFGFgvmodID7qFGCFHcbL_7o2Nt3T0QPLuCKGfGJ8AkY9-M3WKAT9swjvhxXNgoHfc0jm-qNKszgNaB9" rel="nofollow" target="_blank" title="">https://cullinantherapeutics.com/</a>, and follow Cullinan on <a href="https://www.globenewswire.com/Tracker?data=rnNcaITlEoNL0sMLIPhvwxM1VGIxT2bRtUv02xnoN0yd3buthdOi7PV-gPci5ffmYiFtNeRobxp0axm7vP-GhBqTqNkeWNE8YPQEyQP13M8=" rel="nofollow" target="_blank" title="LinkedIn">LinkedIn</a> and <a href="https://www.globenewswire.com/Tracker?data=pHmEmnlashrBddLEo9aVRY0vP6SaeS93roNWFR_22MIaUyGwAH23OH8_ELM3wx_WY4Nv537CRo29AfGJzCUBjQ==" rel="nofollow" target="_blank" title="X">X</a>. Contacts Cullinan Therapeutics Investors Nick Smith +1 401.241.3516 <a href="https://www.globenewswire.com/Tracker?data=nfApll_BF6ROAkNiU1QosyuQA-IfYjqevGdbCByGK5WHdB-EC17CGf1cRNg6-gWLfH6u-I_2RfSNRltTC7yPD-uIT35HJ9O9kUyNmki4wPc=" rel="nofollow" target="_blank" title="Nsmith@cullinantx.com">Nsmith@cullinantx.com</a> Media Rose Weldon +1 215.801.7644 <a href="https://www.globenewswire.com/Tracker?data=Z__-exTsmRVWGItd_tEAyS7WxX1WWHby86LYDW9yf6Z1PVeeTiS5oqz9I1X0hVCaxioaS5M_2alStjKz0g7KJyLdgWmpGOSxBZ5Huft6wUw=" rel="nofollow" target="_blank" title="Rweldon@cullinantx.com">Rweldon@cullinantx.com</a> <img alt="" src='https://ml.globenewswire.com/media/M2VlOGJjZDEtMDUyOC00MjE4LTkxNWYtNzJhOTJmZTIyYmY3LTEyMTc0MjYtMjAyNi0wOS0xNC1lbg==/tiny/Cullinan-Therapeutics-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn